Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $33.00

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price objective upped by The Goldman Sachs Group from $30.00 to $33.00 in a report released on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. The Goldman Sachs Group’s price target suggests a potential upside of 55.29% from the company’s previous close.

Other equities analysts have also issued research reports about the company. Stifel Nicolaus raised their price objective on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Barclays raised their price target on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a report on Thursday, August 15th. HC Wainwright raised their price target on Syndax Pharmaceuticals from $45.00 to $47.00 and gave the company a “buy” rating in a report on Wednesday. Citigroup raised their price target on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a “buy” rating in a report on Friday, August 16th. Finally, JPMorgan Chase & Co. reduced their price target on Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, Syndax Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $35.82.

Syndax Pharmaceuticals Trading Down 0.5 %

Syndax Pharmaceuticals stock traded down $0.10 on Thursday, hitting $21.25. 297,800 shares of the stock traded hands, compared to its average volume of 1,061,382. The firm has a market cap of $1.81 billion, a P/E ratio of -6.30 and a beta of 0.92. The business’s fifty day simple moving average is $19.06 and its 200 day simple moving average is $20.32. Syndax Pharmaceuticals has a 1 year low of $13.14 and a 1 year high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.13) by $0.15. The firm had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $9.16 million. During the same period in the prior year, the business posted ($0.73) EPS. As a group, analysts predict that Syndax Pharmaceuticals will post -3.66 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. purchased a new position in Syndax Pharmaceuticals in the second quarter worth about $27,000. Values First Advisors Inc. purchased a new position in Syndax Pharmaceuticals in the third quarter worth about $30,000. nVerses Capital LLC purchased a new position in Syndax Pharmaceuticals in the second quarter worth about $33,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Syndax Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after purchasing an additional 541 shares during the last quarter. Finally, Quarry LP boosted its position in Syndax Pharmaceuticals by 75.0% in the second quarter. Quarry LP now owns 6,125 shares of the company’s stock worth $126,000 after purchasing an additional 2,625 shares during the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).